YOLFTbeta
00

Harbin Medisan Pharmaceutical Co Ltd

002900 · SHE · Healthcare / Drug Manufacturers - Specialty & Generic

9.97CNY-0.32 (-3.11%)

Price History

Full chart

Market Stats

Previous Close10.29
Open10.24
Day Range9.96 – 10.28
52-Week Range8.93 – 17.19
Volume5.47M
Market Cap4.10B
P/E (TTM)0.00
Forward P/E0.00
EPS-0.92
Dividend Yield0.00%
Beta0.17
50-Day Avg12.83
200-Day Avg11.84

About

Harbin Medisan Pharmaceutical Co., Ltd. engages in the research, development, production, and sale chemical pharmaceutical preparations in China. The company offers various drugs for nervous system, cardiovascular system, systemic anti-infective, muscle and skeletal system, nutritional infusion, and body fluid balance infusion; and other products, including oxaliplatin for injection, calcium folinate for injection, hydroxylcamptothecine injection, tropisetron hydrochloride for injection, tropisetron hydrochloride and glucose injection, gabexate mesylate for injection, bismuth potassium citrate granules, pantoprazole sodium for injection, ambroxol hydrochloride and glucose injection, asarone for injection, paracetamol and tramadol hydrochloride tablets, rifamycin sodium for injection, lornoxicam for injection, vecuronium bromide for injection, and vitamin c for injection. It also provides manufacture, sale, and retail of pharmaceutical, drug development, technology investment consulting, logistics and transportation, medical devices, food, and cosmetics. Harbin Medisan Pharmaceutical Co., Ltd. was founded in 1996 and is headquartered in Harbin, China.

Company Details

  • SectorHealthcare
  • IndustryDrug Manufacturers - Specialty & Generic
  • CEOMr. Jian Fei Qin
  • Employees2.09K
  • HeadquartersThe middle part of Beijing Road, Harbin, China, 150025, China
  • Websitehttps://www.medisan.com.cn

Leadership

  • Mr. Jian Fei QinChairman & President · b. 1963
  • Mr. Zhicheng ZhaoFinancial Director · b. 1975
  • Mr. Yan Fei LiangVP, Board Secretary & Director · b. 1967
  • Xia LiAccounting Supervisor

Financials

Income Statement

Currency: CNY2012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue491.17M601.23M681.52M722.02M760.87M1.15B2.17B2.10B1.34B945.80M1.03B1.19B1.13B789.42M
Growth (%)-+22.41%+13.35%+5.94%+5.38%+50.99%+89.11%-3.24%-36.31%-29.36%+8.73%+15.40%-4.58%-30.29%
Cost of Revenue273.21M284.72M291.44M279.65M294.22M298.09M354.78M513.16M487.25M312.86M360.34M475.55M553.88M491.61M
Gross Profit217.96M316.51M390.08M442.37M466.65M850.74M1.82B1.59B851.63M632.94M668.08M711.23M578.60M297.81M
Gross Margin44.38%52.64%57.24%61.27%61.33%74.05%83.67%75.59%63.61%66.92%64.96%59.93%51.09%37.73%
Operating Expense110.44M195.09M226.51M255.43M270.90M598.03M1.57B1.36B816.37M178.13M627.45M632.21M516.59M573.07M
Operating Income107.52M121.41M163.57M186.94M195.75M252.71M251.00M228.81M35.26M454.81M40.63M79.02M62.01M-275.26M
Operating Margin21.89%20.19%24.00%25.89%25.73%22.00%11.55%10.89%2.63%48.09%3.95%6.66%5.48%-34.87%
EBITDA103.70M138.64M199.59M225.87M271.55M326.88M324.88M313.71M122.62M556.47M160.55M203.86M187.82M-183.87M
EBITDA Margin21.11%23.06%29.29%31.28%35.69%28.45%14.95%14.92%9.16%58.84%15.61%17.18%16.58%-23.29%
Net Income82.72M104.39M146.98M166.30M175.18M181.08M205.81M177.18M29.32M350.95M30.21M73.66M58.68M-339.63M
Net Income Margin16.84%17.36%21.57%23.03%23.02%15.76%9.47%8.43%2.19%37.11%2.94%6.21%5.18%-43.02%
R&D20.82M30.90M50.61M54.02M49.04M69.35M79.01M112.45M112.02M99.92M89.27M112.81M105.22M93.16M
R&D as % of Total Revenue4.24%5.14%7.43%7.48%6.44%6.04%3.64%5.35%8.37%10.56%8.68%9.51%9.29%11.80%
Interest Expense-6.07M7.98M6.57M4.67M5.04M2.06M4.83M9.51M14.59M23.56M24.08M27.29M26.47M
Interest Expense % of Total Revenue-1.01%1.17%0.91%0.61%0.44%0.09%0.23%0.71%1.54%2.29%2.03%2.41%3.35%

Balance Sheet

Currency: CNY2012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets719.01M857.75M970.46M1.05B1.17B2.18B2.51B2.67B2.48B3.07B3.28B3.44B3.80B3.46B
Total Liabilities376.29M492.63M361.30M324.95M358.01M348.80M543.78M820.44M691.18M949.04M1.22B1.29B1.64B1.68B
Total Equity335.87M365.13M609.16M727.97M808.17M1.83B1.95B1.83B1.78B2.10B2.04B2.14B2.16B1.77B
Cash80.25M85.87M93.21M80.85M128.85M354.66M451.69M471.49M661.45M529.83M1.20B991.16M794.07M460.86M
Total Debt72.00M127.00M107.00M90.00M106.00M7.35M58.00M180.00M269.78M487.67M656.73M513.43M714.83M-
Net Debt-8.25M41.13M13.79M9.15M-22.85M-347.31M-393.69M-291.49M-391.67M-42.17M-545.92M-272.79M-79.24M583.65M

Cash Flow

Currency: CNY2012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow123.22M167.10M116.31M200.85M231.18M223.46M292.46M320.14M-4.51M-12.53M144.64M35.69M30.69M-36.25M
Investing Cash Flow-96.49M-174.52M-136.07M-142.19M-107.80M-725.31M-160.47M-127.98M201.29M-278.23M419.25M-260.52M-331.41M-
Financing Cash Flow14.97M7.34M30.58M-69.10M-66.41M721.32M-27.61M-178.09M-2.56M-43.71M-107.12M-15.08M313.85M-
Capital Expenditure91.01M154.13M145.81M141.72M93.88M104.93M78.41M198.63M145.85M73.95M89.22M299.58M346.21M247.73M
Free Cash Flow32.21M12.97M-29.50M59.13M137.31M118.53M214.05M121.51M-150.36M-86.48M55.42M-263.89M-315.52M-283.98M
Dividends Paid4.67M41.96M52.50M54.02M91.39M92.37M107.45M202.53M86.74M24.78M99.13M41.04M104.56M110.28M
FCF to OCF26.14%7.76%-25.36%29.44%59.39%53.04%73.19%37.95%3336.14%690.00%38.31%-739.31%-1028.15%783.39%
Dividend Paid to FCF14.51%323.41%-177.99%91.36%66.56%77.93%50.20%166.68%-57.69%-28.66%178.88%-15.55%-33.14%-38.83%

Earnings

Report DateOct 25, 2017Feb 27, 2018Apr 20, 2018Aug 23, 2018Oct 22, 2018Dec 31, 2018Apr 23, 2019Jun 30, 2019Sep 30, 2019Dec 31, 2019Apr 24, 2020Aug 27, 2020Oct 23, 2020Dec 31, 2020Apr 28, 2021Jun 30, 2021Sep 30, 2021Dec 31, 2021Mar 31, 2022Jun 30, 2022Sep 30, 2022Dec 31, 2022Mar 31, 2023Jun 30, 2023Dec 28, 2023Dec 31, 2023May 16, 2024Jun 30, 2024Oct 9, 2024Dec 31, 2024May 16, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
EPS Estimate------------------------------------
EPS Actual0.140.170.200.260.120.080.170.200.110.090.10-0.01-0.020.021.820.07-0.15-0.61-0.000.070.000.030.120.040.030.050.060.020.050.06-0.09-0.20-0.37-0.41-0.02-0.12
Surprise------------------------------------
TimingAfter-hoursPre-marketAfter-hoursAfter-hoursPre-market-Pre-market-----------------After-hours-After-hours-After-hours-After-hours-----

Key Statistics & Ratios

Market Cap4.10B
Enterprise Value4.57B
Trailing P/E0.00
Forward P/E0.00
Price / Sales5.10
Price / Book2.35
EPS-0.92
Book Value5.46
Revenue (TTM)805.09M
Gross Profit (TTM)263.71M
EBITDA-152.30M
Profit Margin-36.20%
Operating Margin-15.40%
Return on Equity-15.66%
Return on Assets-5.34%
Shares Outstanding316.35M
Shares Float107.86M
Beta0.17
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Dividends

20251×
0.20May 29, 2025
20241×
0.20Jun 5, 2024
20231×
0.10May 31, 2023
20221×
0.32Jun 13, 2022
20211×
0.08Jul 5, 2021
20201×
0.28Jun 30, 2020
20191×
0.65Jun 4, 2019
20181×
0.33Jun 13, 2018

Stock Splits

  • Jun 13, 20181.5:1